View Older Stories View More Recent Stories

Jun 24, 2022 06:45AM Merck (MRK) Announces EU Approval of KEYTRUDA as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection
Jun 24, 2022 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
Jun 23, 2022 09:00AM MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical Cancer Therapies
Jun 23, 2022 05:57AM Merck (MRK) Announces CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of VAXNEUVANCE as an Option for Pneumococcal Vaccination in Infants and Children
Jun 22, 2022 06:28PM CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
Jun 22, 2022 06:46AM Merck (MRK) Announces FDA Approval of VAXNEUVANCE for Prevention of Invasive Pneumococcal Disease in Infants and Children
Jun 22, 2022 06:45AM U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
Jun 21, 2022 04:30PM Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
Jun 21, 2022 04:10PM Merck (MRK) Appoints Chirfi Guindo to Lead Marketing for Merck Human Health
Jun 21, 2022 04:10PM Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
Jun 21, 2022 07:14AM Merck (MRK) Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Jun 21, 2022 06:45AM Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Jun 13, 2022 06:47AM Merck (MRK) Announces FDA Accepted Application for KEYTRUDA as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
Jun 13, 2022 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
Jun 8, 2022 06:51AM Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 7, 2022 06:46AM Merck (MRK) and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Jun 7, 2022 06:45AM Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Jun 7, 2022 06:34AM Merck (MRK) to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
Jun 7, 2022 06:30AM Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
Jun 6, 2022 05:53AM Merck (MRK) Announces Adjuvant Treatment with KEYTRUDA Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage II
Jun 5, 2022 08:00AM Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resecte
May 24, 2022 01:46PM Merck Announces Third-Quarter 2022 Dividend
May 24, 2022 06:46AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breas
May 24, 2022 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Nega
May 20, 2022 08:15AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma
May 20, 2022 08:15AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Re
May 18, 2022 08:00AM MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile Lab
May 10, 2022 06:45AM Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
May 4, 2022 06:45AM Merck to Participate in Bank of America Securities 2022 Healthcare Conference
Apr 29, 2022 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
Apr 29, 2022 06:31AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1
Apr 29, 2022 06:30AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Exp
Apr 28, 2022 06:30AM Merck Announces First-Quarter 2022 Financial Results
Apr 25, 2022 06:45AM Merck (MRK) Reports Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stag
Apr 25, 2022 06:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Ri
Apr 20, 2022 06:46AM Merck (MRK) Appoints Joseph Romanelli to Lead Merck Human Health International
Apr 20, 2022 06:45AM Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022
Apr 14, 2022 06:47AM Merck (MRK) Granted FDA Breakthrough Therapy Designation for V116
Apr 14, 2022 06:45AM Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Di
Apr 8, 2022 06:45AM Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28
Apr 5, 2022 02:00PM MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities
Apr 5, 2022 06:52AM Merck (MRK) to Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
Apr 5, 2022 06:45AM Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
Apr 4, 2022 06:45AM Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
Apr 1, 2022 06:47AM Merck (MRK) Provides Update on FDA Review of sBLA for VAXNEUVANCE for Use in Infants and Children
Apr 1, 2022 06:45AM Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
Apr 1, 2022 06:40AM Merck (MRK), Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Apr 1, 2022 06:40AM Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Mar 31, 2022 09:00AM EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
Mar 31, 2022 07:30AM Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors
View More Recent Stories View Older Stories